Buccal, polar and non-polar spray containing ondansetron

Inactive Publication Date: 2006-09-07
DUGGER HARRY A III +1
View PDF98 Cites 81 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0007] A buccal aerosol spray or soft bite gelatin capsule using a polar or non-polar solvent has now been developed whic

Problems solved by technology

However, formulations suitable for such administrati

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Buccal, polar and non-polar spray containing ondansetron
  • Buccal, polar and non-polar spray containing ondansetron

Examples

Experimental program
Comparison scheme
Effect test

Example

Example 1

Biologically Active Peptides Including Peptide Hormones

[0070] A. Cyclosporine Lingual Spray preferredmost preferredAmountsamountamountcyclosporine5-5010-3515-25water5-207.5-50 9.5-12 ethanol5-607.5-50 10-20polyethylene glycol20-60 30-4535-40flavors0.1-5  1-42-3

[0071] B. Cyclosporine Non-Polar Lingual Spray preferredmost preferredAmountsamountamountcyclosporine 1-50 3-40 5-30Migylol202530-40Polyoxyethylated castor oil202530-40Butane25-8030-7033-50flavors0.1-5  1-42-3

[0072] C. Cyclosporine Non-Polar Bite Caosule preferredmost preferredAmountsamountamountcyclosporine 1-355-2510-20olive oil25-6035-55 30-45polyoxyethylated25-6035-55 30-45oleic glyceridesflavors0.1-5  1-4 2-3

[0073] D. Cyclosporine Bite Capsule preferredmost preferredAmountsamountamountcyclosporine5-5010-3515-25polyethylene20-60 30-4535-40glycolglycerin5-307.5-25 10-20propylene glycol5-307.5-25 10-20flavors0.1-10  1-83-6

[0074] E. Sermorelin (as the Acetate) Lingual Spray preferredmostAmountsamountpreferreds...

Example

Example 2

CNS Active Amines and Their Salts: Including but not Limited to Tricyclic Amines, GABA Analogues, Thiazides, Phenothiazine Derivatives, Serotonin Antagonists and Serotonin Reuptake Inhibitors

[0078] A. Sumatriptan Succinate Lingual Spray preferredmost preferredAmountsamountamountsumatriptan succinate0.5-30    1-2010-15ethanol5-607.5-5010-20propylene glycol5-307.5-2010-15polyethylene glycol0-60 30-4535-40water5-307.5-2010-15flavors0.1-5   1-42-3

[0079] B. Sumatriptan Succinate Bite Capsule preferredmost preferredAmountsamountamountsumatriptan succinate0.01-5  0.05-3.5 0.075-1.75 polyethylene glycol25-7030-6035-50glycerin25-7030-6035-50flavors0.1-10 1-83-6

[0080] C. Clozepine Lingual Spray preferredmost preferredAmountsamountamountclozepine0.5-30    1-2010-15ethanol5-607.5-5010-20propylene glycol5-307.5-2010-15polyethylene glycol0-60 30-4535-40water5-307.5-2010-15flavors0.1-5   1-42-3

[0081] D. Clozepine Non-Polar Lingual Spray with Propellant preferredmost preferredAmount...

Example

Example 3

Sulfonylureas

[0085] A. Glyburide Lingual Spray preferredmost preferredAmountsamountamountglyburide0.25-25  0.5-200.75-15  ethanol5-60−7.5-50  10-20propylene glycol5-307.5-2010-15polyethylene glycol0-60 30-4535-40water2.5-30    5-20 6-15flavors0.1-5   1-42-3

[0086] B. Glyburide Non-Polar Bite Capsule preferredmost preferredAmountsamountamountglyburide0.01-10  0.025-7.5 0.1-4 olive oil30-6035-55 30-50polyoxyethylated oleic30-6035-55 30-50glyceridesflavors0.1-5  1-4 2-3

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Timeaaaaaaaaaa
Login to view more

Abstract

Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide ondansetron for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, ondansetron, and optional flavoring agent; formulation II: aqueous polar solvent, ondansetron, optionally flavoring agent, and propellant; formulation III: non-polar solvent, ondansetron, and optional flavoring agent; formulation IV: non-polar solvent, ondansetron, optional flavoring agent, and propellant; formulation V: a mixture of a polar solvent and a non-polar solvent, ondansetron, and optional flavoring agent; formulation VI: a mixture of a polar solvent and a non-polar solvent, ondansetron, optional flavoring agent, and propellant.

Description

CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation-in-part of application Ser. No. 10 / 230,085, filed Aug. 29, 2002, now pending, which is a continuation-in-part of application Ser. No. 09 / 537,118, filed Mar. 29, 2000 which is a continuation-in-part of the U.S. national phase designation of PCT / US97 / 17899 filed Oct. 1, 1997, the disclosures of which are incorporated by reference herein in their entirety.BACKGROUND OF THE INVENTION [0002] It is known that certain biologically active compounds are better absorbed through the oral mucosa than through other routes of administration, such as through the stomach or intestine. However, formulations suitable for such administration by these latter routes present their own problems. For example, the biologically active compound must be compatible with the other components of the composition such as propellants, solvents, etc. Many such formulations have been proposed. For example, U.S. Pat. No. 4,689,233, Dvorsk...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61L9/04A61K9/00A61K9/40A61K31/4178A61K31/573A61P1/08A61P23/00A61P25/22
CPCA61K31/4178A61K31/573A61K47/10A61K9/006A61K9/0056A61K2300/00A61P1/08A61P23/00A61P25/22A61P43/00A61K9/12
Inventor DUGGER, HARRY A. IIIABD EL-SHAFY, MOHAMMED
Owner DUGGER HARRY A III
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap